TY - JOUR
T1 - Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent
AU - Rha, Seung Woon
AU - Kuchulakanti, Pramod K.
AU - Pakala, Rajbabu
AU - Cheneau, Edouard
AU - Fournadjiev, Jana A.
AU - Pinnow, Ellen
AU - GebreEyesus, Afework
AU - Aggrey, George
AU - Wang, Zuyue
AU - Pichard, Augusto D.
AU - Satler, Lowell F.
AU - Kent, Kenneth M.
AU - Lindsay, Joseph
AU - Waksman, Ron
PY - 2004/10/15
Y1 - 2004/10/15
N2 - Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions. This retrospective, observational study aimed to evaluate the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients treated with sirolimus-eluting stents (Cypher) and found that bivalirudin is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.
AB - Bivalirudin (Angiomax) is increasingly used as a substitute for heparin in a variety of percutaneous coronary interventions. This retrospective, observational study aimed to evaluate the efficacy and safety of bivalirudin compared with heparin as an antithrombotic regimen in patients treated with sirolimus-eluting stents (Cypher) and found that bivalirudin is clinically safe and feasible, with fewer vascular and ischemic complications compared with heparin.
UR - https://www.scopus.com/pages/publications/5044227780
UR - https://www.scopus.com/pages/publications/5044227780#tab=citedBy
U2 - 10.1016/j.amjcard.2004.06.065
DO - 10.1016/j.amjcard.2004.06.065
M3 - Article
C2 - 15476623
AN - SCOPUS:5044227780
SN - 0002-9149
VL - 94
SP - 1047
EP - 1050
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 8
ER -